James SL, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–858.
Gore M, Tai KS, Sadosky A, Leslie D, Stacey BR. Use and costs of prescription medications and alternative treatments in patients with osteoarthritis and chronic low back pain in community-based settings. Pain Pract. 2012;12(7):550–60.
Hart OR, Uden RM, McMullan JE, Ritchie MS, Williams TD, Smith BH. A study of National Health Service management of chronic osteoarthritis and low back pain. Prim Health Care Res Dev. 2015;16(02):157–66.
Piccoliori G, Engl A, Gatterer D, Sessa E, in der Schmitten J, Abholz H-H. Management of low back pain in general practice – is it of acceptable quality: an observational study among 25 general practices in South Tyrol (Italy). BMC Fam Pract. 2013;14(1):148.
Ivanova JI, Birnbaum HG, Schiller M, Kantor E, Johnstone BM, Swindle RW. Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care. Spine J. 2011;11(7):622–32.
Williams CM, Maher CG, Hancock MJ, McAuley JH, McLachlan AJ, Britt H, et al. Low back pain and best practice care. Arch Intern Med. 2010;170(3):271.
Bishop P, Wing P. Compliance with clinical practice guidelines in family physicians managing worker’s compensation board patients with acute lower back pain. Spine J. 2003;3(6):442–50.
Almeida M, Saragiotto B, Richards B, Maher CG. Primary care management of non-specific low back pain: key messages from recent clinical guidelines. Med J Aust. 2018;208(6):272–5.
National Institute for Health and Care Excellence (NICE) 2016. Low back pain and sciatica in over 16 s: assessment and management (NG59). https://www.nice.org.uk/guidance/ng59. Accessed 20 February 2020.
Wambeke P, Desomer A, Ailliet L, Berquin A, Demoulin C, Depreitere B, et al. Low back pain and radicular pain: assessment and management. Belgian Health Care Knowledge Centre (KCE). 2017.
Qaseem A, Wilt TJ, McLean RM, Forciea MA. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American college of physicians. Ann Intern Med. 2017;166(7):514.
Shmagel A, Ngo L, Ensrud K, Foley R. Prescription medication use among community-based U.S. adults with chronic low back pain: a cross-sectional population based study. J Pain. 2018;19(10):1104–12.
Thackeray A, Hess R, Dorius J, Brodke D, Fritz J. Relationship of opioid prescriptions to physical therapy referral and participation for medicaid patients with new-onset low back pain. J Am Board Fam Med. 2017;30(6):784–94.
Mathieson S, Valenti L, Maher CG, Britt H, Li Q, McLachlan AJ, et al. Worsening trends in analgesics recommended for spinal pain in primary care. Eur Spine J. 2018;27(5):1136–45.
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–66.
Harmer CJ, Duman RS, Cowen PJ. How do antidepressants work? New perspectives for refining future treatment approaches. The Lancet Psychiatry. 2017;4(5):409–18.
Cohen SP, Abdi S. New developments in the use of tricyclic antidepressants for the management of pain. Curr Opin Anaesthesiol. 2001;14(5):505–11.
Koes BW, Backes D, Bindels PJE. Pharmacotherapy for chronic non-specific low back pain: current and future options. Expert Opin Pharmacother. 2018;19(6):537–45.
Mafi JN, McCarthy EP, Davis RB, Landon BE. Worsening trends in the management and treatment of back pain. JAMA Intern Med. 2013;173(17):1573.
Salerno SM, Browning R, Jackson JL. The effect of antidepressant treatment on chronic back pain. Arch Intern Med. 2002;162(1):19.
Staiger TO, Gaster B, Sullivan MD, A Deyo R. Systematic review of antidepressants in the treatment of chronic low back pain. Spine. 2003;28(22):2540–5.
Schnitzer TJ, Ferraro A, Hunsche E, Kong SX. A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back pain. J Pain Symptom Manage. 2004;28(1):72–95.
Urquhart DM, Hoving JL, Assendelft WJ, Roland M, van Tulder MW. Antidepressants for non-specific low back pain. Cochrane Database Syst Rev. 2008;44(8):085201.
Ferraro MC, Bagg MK, Folly de Campos T, McAuley JH. RADICAL: Systematic review of anti-depressant medicines if considered analgesics for low back pain. 2019. https://osf.io/6gurb/
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–58.
United States Food and Drugs Administration. Code of Federal Regulations Title 21. 2018. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr = 314.80. Accessed 31 July 2019
Bagg MK, McLachlan AJ, Maher CG, Kamper SJ, Williams CM, Henschke N, et al. Paracetamol, NSAIDS and opioid analgesics for chronic low back pain: a network meta-analysis. Cochrane Database Syst Rev. 2018(6):CD013045.
Bagg MK, O’Hagan E, Zahara P, Wand BM, Hübscher M, Moseley GL, et al. Systematic reviews that include only published data may overestimate the effectiveness of analgesic medicines for low back pain: a systematic review and meta-analysis. J Clin Epidemiol. 2020;124:149-159.
Dionne CE, Dunn KM, Croft PR, Nachemson AL, Buchbinder R, Walker BF, et al. A consensus approach toward the standardization of back pain definitions for use in prevalence studies. Spine. 2008;33(1):95–103.
Koes BW, van Tulder MW, Peul WC. Diagnosis and treatment of sciatica. BMJ. 2007;334(7607):1313–7.
WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. 2020. https://www.whocc.no/atc_ddd_index/. Accessed 31 July 2019
U.S. Food and Drug Administration. Drugs@FDA. 2020. https://www.fda.gov/drugs. Accessed 31 July 2019
Australian Government Department of Health Therapeutic Goods Administration. Australian Register of Therapeutic Goods. 2020. https://www.tga.gov.au/searching-australian-register-therapeutic-goods-artg. Accessed 31 July 2019
Medicines and Healthcare Products Regulatory Agency. MHRA Products. 2020 https://products.mhra.gov.uk. Accessed 31 July 2019
European Medicines Agency. Medicines. 2020. https://www.ema.europa.eu/en/medicines. Accessed 31 July 2019
Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). Cochrane Collaboration; 2011.
Furlan AD, Malmivaara A, Chou R, Maher CG, Deyo RA, Schoene M, et al. 2015 updated method guideline for systematic reviews in the cochrane back and neck group. Spine. 2015;40(21):1660–73.
Furukawa TA, Salanti G, Atkinson LZ, Leucht S, Ruhe HG, Turner EH, et al. Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. BMJ Open. 2016;6(7):e010919.
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al., Cochrane Handbook for Systematic Reviews of Interventions Version 6.0. Wiley; 2019.
Busse JW, Bartlett SJ, Dougados M, Johnston BC, Guyatt GH, Kirwan JR, et al. Optimal strategies for reporting pain in clinical trials and systematic reviews: recommendations from an OMERACT 12 workshop. J Rheumatol. 2015;42(10):1962–70.
R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2019. https://www.r-project.org/
Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36(3):1–48.
PDR LLC. Prescriber’s digital reference. 2020. https://www.pdr.net. Accessed 24 February 2020
StataCorp LLC. Stata Statistical Software. College Station, TX; 2019.
Ferreira ML, Herbert RD, Crowther MJ, Verhagen A, Sutton AJ. When is a further clinical trial justified? BMJ. 2012;345:e5913.
Langan D, Higgins JPT, Gregory W, Sutton AJ. Graphical augmentations to the funnel plot assess the impact of additional evidence on a meta-analysis. J Clin Epidemiol. 2012;65(5):511–9.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.
Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.
Alcoff J, Jones E, Rust P, Newman R. Controlled trial of imipramine for chronic low back pain. J Fam Pract. 1982;14(5):841–6.
Atkinson JH, Slater MA, Capparelli EV, Wallace MS, Zisook S, Abramson I, et al. Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain. J Clin Psychopharmacol. 2007;27(2):135–42.
Konno S, Oda N, Ochiai T, Alev L. Randomized, double-blind, placebo-controlled phase III trial of duloxetine monotherapy in Japanese patients with chronic low back pain. Spine. 2016;41(22):1709–17.
Pheasant H, Bursk A, Goldfarb J, Azen SP, Weiss JN, Borelli L. Amitriptyline and chronic low-back pain: a randomized double-blind crossover study. Spine. 1983;8(5):552–7.
Schliessbach J, Siegenthaler A, Bütikofer L, Limacher A, Juni P, Vuilleumier PH, et al. Effect of single-dose imipramine on chronic low-back and experimental pain. A randomized controlled trial. PLoS One. 2018;13(5):e0195776.
Schukro RP, Oehmke MJ, Geroldinger A, Heinze G, Kress H-G, Pramhas S. Efficacy of duloxetine in chronic low back pain with a neuropathic component. Anesthesiology. 2016;124(1):150–8.
Skljarevski V, Desaiah D, Liu-Seifert H, Zhang Q, Chappell AS, Detke MJ, et al. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine. 2010;35(13):E578–85.
Skljarevski V, Ossanna M, Liu-Seifert H, Zhang Q, Chappell A, Iyengar S, et al. A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain. Eur J Neurol. 2009;16(9):1041–8.
Skljarevski V, Zhang S, Desaiah D, Alaka KJ, Palacios S, Miazgowski T, et al. Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial. J Pain. 2010;11(12):1282–90.
Treves R, Montane De La Roque P, Dumond JJ, Bertin P, Arnaud M, Desproges-Gotteron R. Prospective study of the analgesic action of clomipramine versus placebo in refractory low back pain and sciatica (68 cases). Rev Rhum Mal Osteoartic. 1991;58(7):549–52.
Urquhart DM, Wluka AE, van Tulder M, Heritier S, Forbes A, Fong C, et al. Efficacy of low-dose amitriptyline for chronic low back pain. JAMA Intern Med. 2018;178(11):1474–81.
Atkinson JH, Slater MA, Wahlgren DR, Williams RA, Zisook S, Pruitt SD, et al. Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity. Pain. 1999;83(2):137–45.
Atkinson JH, Slater MA, Williams RA, Zisook S, Patterson TL, Grant I, et al. A placebo-controlled randomized clinical trial of nortriptyline for chronic low back pain. Pain. 1998;76(3):287–96.
Dickens C, Jayson M, Sutton C, Creed F. The relationship between pain and depression in a trial using paroxetine in sufferers of chronic low back pain. Psychosomatics. 2000;41(6):490–9.
Goodkin K, Gullion CM, Agras WS. A randomized, double-blind, placebo-controlled trial of trazodone hydrochloride in chronic low back pain syndrome. J Clin Psychopharmacol. 1990;10(4):269–78.
Gould HM, Atkinson JH, Chircop-Rollick T, DʼAndrea J, Garfin S, Patel SM, et al. A randomized placebo-controlled trial of desipramine, cognitive behavioral therapy, and active placebo therapy for low back pain. Pain. 2020;161(6):1341–9.
Jenkins DG, Ebbutt AF, Evans CD. Tofranil in the treatment of low back pain. J Int Med Res. 1976;4(2):28–40.
Johnson K, Chatterjee N, Noor N, Crowell A, McCue R, Mackey S. Effects of duloxetine and placebo in patients with chronic low back pain. J Pain. 2011;12(4):P49.
Katz J, Pennella-Vaughan J, Hetzel RD, Kanazi GE, Dworkin RH. A randomized, placebo-controlled trial of bupropion sustained release in chronic low back pain. J Pain. 2005;6(10):656–61.
Veroniki AA, Jackson D, Viechtbauer W, Bender R, Bowden J, Knapp G, et al. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016;7(1):55–79.
Chou R, Deyo R, Friedly J, Skelly A, Weimer M, Fu R, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. Ann Intern Med. 2017;166(7):480.
Oliveira CB, Maher CG, Pinto RZ, Traeger AC, Lin C-WC, Chenot J-F, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J. 2018;27(11):2791–803.
Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105–21.
Lee H, Lamb SE, Bagg MK, Toomey E, Cashin AG, Moseley GL. Reproducible and replicable pain research: a critical review. Pain. 2018;159(9):1683–9.
Baudard M, Yavchitz A, Ravaud P, Perrodeau E, Boutron I. Impact of searching clinical trial registries in systematic reviews of pharmaceutical treatments: methodological systematic review and reanalysis of meta-analyses. BMJ. 2017;356:j448.
Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ. 2012;344:d7202.